DE602005027737D1 - Verfahren zur antikörpererzeugung - Google Patents

Verfahren zur antikörpererzeugung

Info

Publication number
DE602005027737D1
DE602005027737D1 DE602005027737T DE602005027737T DE602005027737D1 DE 602005027737 D1 DE602005027737 D1 DE 602005027737D1 DE 602005027737 T DE602005027737 T DE 602005027737T DE 602005027737 T DE602005027737 T DE 602005027737T DE 602005027737 D1 DE602005027737 D1 DE 602005027737D1
Authority
DE
Germany
Prior art keywords
antibody
amino acid
methods
acid sequence
substitutable position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005027737T
Other languages
English (en)
Inventor
Fernando Jose Rebelo Do Couto
Kristin B Hendricks
Stacey Ellen Wallace
Guo-Liang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epitomics Inc
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitomics Inc filed Critical Epitomics Inc
Publication of DE602005027737D1 publication Critical patent/DE602005027737D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
DE602005027737T 2004-11-08 2005-11-02 Verfahren zur antikörpererzeugung Active DE602005027737D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/984,473 US7462697B2 (en) 2004-11-08 2004-11-08 Methods for antibody engineering
PCT/US2005/039930 WO2006050491A2 (en) 2004-11-08 2005-11-02 Methods for antibody engineering

Publications (1)

Publication Number Publication Date
DE602005027737D1 true DE602005027737D1 (de) 2011-06-09

Family

ID=36316567

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027737T Active DE602005027737D1 (de) 2004-11-08 2005-11-02 Verfahren zur antikörpererzeugung

Country Status (12)

Country Link
US (5) US7462697B2 (de)
EP (1) EP1819830B1 (de)
JP (2) JP2008518619A (de)
CN (2) CN101080496A (de)
AT (1) ATE507302T1 (de)
CA (2) CA2585742C (de)
DE (1) DE602005027737D1 (de)
DK (1) DK1819830T3 (de)
ES (1) ES2362792T3 (de)
HK (1) HK1200854A1 (de)
PT (1) PT1819830E (de)
WO (1) WO2006050491A2 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP3050963B1 (de) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptiden durch regulierung der anordnung
IN2014DN10515A (de) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
EP3345616A1 (de) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
US20070269868A1 (en) * 2006-05-19 2007-11-22 Carvalho Jensen Anne E Culture method for obtaining a clonal population of antigen-specific B cells
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
WO2008144757A1 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
AU2013204593B2 (en) * 2007-05-21 2016-01-21 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
JP5833823B2 (ja) 2007-05-21 2015-12-16 アルダーバイオ・ホールディングズ・エルエルシー Ｉｌ−６に対する抗体およびその使用
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US20090074780A1 (en) * 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2009000098A2 (en) * 2007-06-25 2008-12-31 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
KR101637533B1 (ko) * 2007-08-20 2016-07-11 글락소 그룹 리미티드 제조 방법
PL3059246T3 (pl) 2007-09-26 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Zmodyfikowany region stały przeciwciała
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2259795B1 (de) * 2008-03-26 2016-04-06 Epitomics, Inc. Anti-vegf-antikörper
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
PL2307454T3 (pl) 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Trwałe i rozpuszczalne przeciwciała hamujące VEGF
HUE053548T2 (hu) * 2008-06-25 2021-07-28 Novartis Ag Stabil és szolúbilis, TNF-gátló ellenanyagok
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
BRPI1013373B1 (pt) 2009-03-30 2022-01-18 Edimer Biotech S.A. Anticorpo monoclonal anti-edar agonista isolado, molécula de ácido nucleico isolada, vetor de expressão, microrganismo, composição farmacêutica, e, kit farmacêutico
ES2495367T3 (es) 2009-04-29 2014-09-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Anticuerpos monoclonales de ERG
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CA2782936C (en) 2009-12-10 2019-06-18 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US9150641B2 (en) * 2009-12-22 2015-10-06 Hoffmann—La Roche Inc. Sequence dependent aggregation
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
RU2013115927A (ru) * 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
RS57038B1 (sr) 2010-11-17 2018-05-31 Chugai Pharmaceutical Co Ltd Multi-specifičan antigen-vezujući molekul koji ima alternativnu funkciju funkciji faktora viii koagulacije krvi
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
US8753634B2 (en) 2011-03-03 2014-06-17 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
JP6125489B2 (ja) 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
SG10201500953YA (en) 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
US9580496B2 (en) * 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
PT2717917T (pt) 2011-07-05 2016-07-27 Bioasis Technologies Inc Conjugados de anticorpos p97
EP2732269B1 (de) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-basiertes verfahren zur erzeugung einer antikörpersequenz
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
EP2739649B1 (de) 2011-08-05 2017-09-27 Bioasis Technologies Inc. P97-fragmente mit transferaktivität
US9988687B2 (en) 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (de) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
JP6117225B2 (ja) 2011-11-02 2017-04-19 アペクシジェン， インコーポレイテッド 抗ｋｄｒ抗体およびその使用方法
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
EP2928920A1 (de) * 2012-12-05 2015-10-14 Dutalys GmbH Zweifaches targeting
CN103145834B (zh) * 2013-01-17 2015-03-18 广州泰诺迪生物科技有限公司 一种抗体人源化改造方法
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CN105189551B (zh) 2013-03-14 2021-03-05 埃派斯进有限公司 抗-rankl抗体及其使用方法
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10465186B2 (en) 2013-08-19 2019-11-05 Epitomics, Inc. Antibody identification by lineage analysis
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
AU2014351611B2 (en) * 2013-11-19 2020-04-23 Janssen Biotech, Inc. Humanised anti kallikrein-2 antibody
MX371298B (es) 2013-12-03 2020-01-23 Harvard College Métodos y reactivos para la evaluación de diabetes gestacional.
JP6691060B2 (ja) 2014-01-17 2020-04-28 グリセリックス リミティド 診断用の細胞表面前立腺癌抗原
CA2935195A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
EP3134439B1 (de) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101618458B1 (ko) 2014-11-28 2016-05-10 강원대학교산학협력단 항체에서 항원-항체 결합력과 양의 상관관계를 갖는 아미노산 서열에 대한 정보를 얻는 방법
CR20170326A (es) 2014-12-19 2017-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
US9765135B2 (en) 2014-12-19 2017-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016131058A1 (en) 2015-02-13 2016-08-18 Biommune Technologies Inc. Antibodies to l-type voltage gated channels and related methods
WO2016136933A1 (ja) 2015-02-27 2016-09-01 中外製薬株式会社 Ｉｌ－６関連疾患治療用組成物
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
US11155636B2 (en) * 2016-06-14 2021-10-26 Agency For Science, Technology And Research PRL3 antibody
US20190352426A1 (en) 2016-08-03 2019-11-21 Achaogen, Inc. Plazomicin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
EP3740509A4 (de) 2018-01-17 2022-06-22 Apexigen, Inc. Anti-pd-l1-antikörper und verfahren zur verwendung
JP2021525779A (ja) 2018-06-08 2021-09-27 ヴェンタナ メディカル システムズ， インク． 機能性および製造可能性を改善するための普遍的なまたは正規化された抗体フレームワーク
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
FI3830132T3 (fi) * 2018-07-31 2023-01-13 Humanisoituja vasta-aineita psma:ta vastaan
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
CN115819575B (zh) * 2022-08-24 2023-06-27 武汉爱博泰克生物科技有限公司 针对人肿瘤坏死因子-α的单克隆抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6093853A (en) * 1997-07-04 2000-07-25 Nok Corporation Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US7115716B2 (en) * 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
JP4335130B2 (ja) * 2002-04-30 2009-09-30 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する抗体
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
EP3323887A3 (de) * 2003-01-17 2018-09-12 DuPont Nutrition Biosciences ApS Verfahren zur vor-ort-herstellung einer emulsion in einem lebensmittel
ES2457538T3 (es) * 2003-02-20 2014-04-28 Seattle Genetics, Inc. Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
CA2517802A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein tyrosine phosphatase-prl-1 a a marker and therapeutic target for pancreatic cancer
AU2003259718A1 (en) * 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering

Also Published As

Publication number Publication date
CA2901238A1 (en) 2006-05-11
CN103980362A (zh) 2014-08-13
US7462697B2 (en) 2008-12-09
US8404816B2 (en) 2013-03-26
CA2901238C (en) 2020-03-24
JP2012095654A (ja) 2012-05-24
WO2006050491A3 (en) 2006-12-28
US20090155824A1 (en) 2009-06-18
WO2006050491A2 (en) 2006-05-11
ES2362792T3 (es) 2011-07-13
EP1819830A2 (de) 2007-08-22
JP5096611B2 (ja) 2012-12-12
US20120003671A1 (en) 2012-01-05
PT1819830E (pt) 2011-07-20
DK1819830T3 (da) 2011-07-04
US7960517B2 (en) 2011-06-14
CN101080496A (zh) 2007-11-28
ATE507302T1 (de) 2011-05-15
US10613094B2 (en) 2020-04-07
CA2585742C (en) 2016-04-12
JP2008518619A (ja) 2008-06-05
EP1819830A4 (de) 2009-03-11
CA2585742A1 (en) 2006-05-11
US20060099204A1 (en) 2006-05-11
US20120329069A1 (en) 2012-12-27
HK1200854A1 (en) 2015-08-14
EP1819830B1 (de) 2011-04-27
US20150038370A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
DE602005027737D1 (de) Verfahren zur antikörpererzeugung
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
NL300919I2 (nl) Brodalumab
ATE477277T1 (de) Weniger immunogene bindungsmoleküle
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
EP3202786A3 (de) Sequenzbasierte herstellung und optimierung von einzelkettenantikörpern
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
BR112012017124A2 (pt) método de modificação polipeptídica para purificação de multímeros polipeptídicos
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2009000098A3 (en) Sequence based engineering and optimization of single chain antibodies
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2008135446A3 (en) Klebsiella antigens
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
WO2010092176A3 (en) Nontypable haemophilus influenzae antigens
WO2013087857A3 (de) Antikörper gegen toxine von c. difficile
UA101142C2 (ru) Способ разработки антитела
EP3103810A3 (de) Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
NZ578068A (en) Allergen-binding ige monoclonal antibodies and method for preparing hypoallergens
ATE531799T1 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper
WO2005000896A3 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof